In the MADIT-CRT trial, in which 654 patients with mild HF symptoms were randomized to CRT or implantable cardioverter defibrillator, an elevated Gal-3 concentration was a significant and independent predictor of nonfatal HF event or death [116]. This evidence concerns the gene LGALS3 and hydrops fetalis.